Pharmaceutical

UroGen Pharma (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the pricing of its public offering of 1,463,414 ordinary shares, at a public offering price of $41.00 per share for gross proceeds of approximately $60.0 million, before deducting underwriting discounts …

UroGen Pharma (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the pricing of its public offering of 1,463,414 ordinary shares, at a public offering price of $41.00 per share for gross proceeds of approximately $60.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
As quoted in the press release:

Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Oppenheimer & Co. Inc. is acting as lead manager for the offering. Ladenburg Thalmann & Co. Inc. and National Securities Corporation are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on January 18, 2018.

Click here to read the full press release.

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1827.54+0.47
Silver21.15+0.03
Copper3.740.00
Palladium1879.51+6.50
Platinum911.26+4.32
Oil107.06+2.79
Heating Oil4.24+0.02
Natural Gas6.17-0.07

DOWNLOAD FREE REPORTS

×